I agree, $2.75 is undercooked.
Using my US$75m FY23 revenue estimate from the Investor Update thread and a 25% EBIT margin (upper end of company FY22 guidance but expected to expand with expanding revenue, so probably conservative) gives a FY23 EBIT estimate of US$18.75m = AUD$26.2m.
That gives a current FY23 forward PE of about 14.5X and at a price of $2.75 a forward PE of 18.1X.
With additional upside from the healthcare business not factored into these numbers, this is ridiculously cheap for a company growing revenue at 74%
I agree, $2.75 is undercooked.Using my US$75m FY23 revenue...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.5¢ |
Change
-0.020(2.05%) |
Mkt cap ! $164.8M | |||
| Open | High | Low | Value | Volume |
| 96.0¢ | 96.0¢ | 95.5¢ | $7.364K | 7.685K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2336 | 95.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.5¢ | 1086 | 1 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| CGS (ASX) Chart |